ALX ONCOLOGY HOLDINGS INC (ALXO)
US00166B1052 - Common Stock
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an...
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus...
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023
ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the fourth quarter of 2023.
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ALX Oncology Holdings (NASDAQ:ALXO) just reported results for the fourth quarte...
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an...
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO,...
Commit To Buy ALX Oncology Holdings At $12, Earn 36.4% Annualized Using Options
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
7 Small-Cap Stocks That Wall Street Loves for Good Reason
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Noteworthy Friday Option Activity: CRSR, ALXO, FCX
Jefferies raises ALX Oncology to buy, cites upcoming catalysts (NASDAQ:ALXO)
Jefferies has raised its rating on ALX Oncology (ALXO) to buy, citing significant upcoming catalysts in 2024. Read more here.
Noteworthy Wednesday Option Activity: OMI, ALXO, SPOT
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an...
ALX Oncology Announces November Investor Conference Participation
ALX Oncology Announces November Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...
Commit To Buy ALX Oncology Holdings At $7.50, Earn 41.9% Annualized Using Options
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an...
ALX Oncology stock rockets 27% after being halted for volatility (NASDAQ:ALXO)
ALX Oncology shares surged 27% in late trading after being halted for volatility. The stock soared earlier in the week on positive drug data. Read more here.
ALX Oncology announces pricing of its public offering (NASDAQ:ALXO)
ALX Oncology announces underwritten public offering, priced at $6.38 per share, to fund clinical development and general corporate purposes.
ALX Oncology Announces Pricing of Public Offering
ALX Oncology Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an...